title: Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells.
abstract: Although intravenous administration of high levels of cisplatin (CDDP) are limited due to its severe side effects, efficient delivery of CDDP directly to the tumor should improve the therapeutic response while potentially by-passing significant side effects. High loading of CDDP into liposomes is one technique that could be used as a potential drug delivery system. Since cis-diamminedinitratoplatinum (CDDP3) is highly soluble in water and converts to CDDP in the presence of chloride ions, we encapsulated CDDP3 into liposomes in the absence of chloride ions and supplemented chloride ions to prepare CDDP-encapsulated liposomes (CDDP-Lip) resulting in a significantly improved loading efficiency of CDDP. We further conjugated the CDDP-Lip with Sialyl Lewis(X) (CDDP-SLX-Lip) because we previously demonstrated Sialyl Lewis(X) enhanced efficient accumulation of liposomes into tumors in vivo. CDDP-SLX-Lip treated mice showed a survival rate of 75% at 14 days even if a lethal level of CDDP was injected into mice. Loss of body weight was negligible and no histological abnormality was found in a variety of normal tissues. Accumulation of CDDP-SLX-Lip was about 6 times more than that of CDDP-Lip or CDDP. As the result, there was better antitumor activity of CDDP-SLX-Lip than that of CDDP-Lip with significantly less toxic effects in normal tissues.
authors.affiliation: R&D Division, Katayama Chemical Industries Co, LTD, Minoh, Osaka 562-0015, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hirai
authors.forename: H
authors.initials: H
authors.lastname: Minematsu
authors.forename: Y
authors.initials: Y
authors.lastname: Hiramatsu
authors.forename: H
authors.initials: H
authors.lastname: Kitagawa
authors.forename: T
authors.initials: T
authors.lastname: Otani
authors.forename: S
authors.initials: S
authors.lastname: Iwashita
authors.forename: T
authors.initials: T
authors.lastname: Kudoh
authors.forename: L
authors.initials: L
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: D S
authors.initials: DS
authors.lastname: Salomon
authors.forename: K
authors.initials: K
authors.lastname: Igarashi
authors.forename: M
authors.initials: M
authors.lastname: Chikuma
authors.forename: M
authors.initials: M
authors.lastname: Seno
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods*; D019040:E-Selectin / Q000378:metabolism; D005260:Female; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D009844:Oligosaccharides / Q000008:administration & dosage* / Q000737:chemistry; D000080506:Sialyl Lewis X Antigen; D015996:Survival Rate; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D019040:E-Selectin; D008081:Liposomes; D009844:Oligosaccharides; D000080506:Sialyl Lewis X Antigen; D002945:Cisplatin